A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.

  title={A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.},
  author={Yang Yang and Peter B. Gilbert and Ira M. Longini and M. Elizabeth Halloran},
  journal={The annals of applied statistics},
  volume={2 4},
In vaccine studies for infectious diseases such as human immunodeficiency virus (HIV), the frequency and type of contacts between study participants and infectious sources are among the most informative risk factors, but are often not adequately adjusted for in standard analyses. Such adjustment can improve the assessment of vaccine efficacy as well as the assessment of risk factors. It can be attained by modeling transmission per contact with infectious sources. However, information about… 

Figures and Tables from this paper

Statistical Communications in Infectious Diseases

Objectives: Using the MTN-020/ASPIRE HIV prevention trial as a motivating example, our objective is to construct a joint model for the HIV exposure process through vaginal intercourse and the time to

Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials

The proposed joint modeling, along with the proposed empirical Bayes estimation approach, can provide valid estimation of the per-exposure efficacy of a preventive intervention.

Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Bayesian statistics, which provide clearly interpretable statements about probabilities that the vaccine efficacy takes certain values, provide more information for weighing the evidence about efficacy than do frequentist statistics alone.

Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials.

Several methods are discussed that can improve understanding of the effects of infectious disease interventions and risk factors by assessing the impact of frailty, and whether the results of the RV144 and CAPRISA trials are consistent with an attenuation of the average RR due to frailty.

Design and Analysis of Vaccine Studies

and Examples.- Overview of Vaccine Effects and Study Designs.- Immunology and Early Phase Trials.- Binomial and Stochastic Transmission Models.- and Deterministic Models.- Evaluating Protective

Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak

It is suggested that comprehensive review articles could not serve as a source to clarify and contextualize the uncertainties around the EVD outbreak, perhaps due to adherence to technical accuracy at the expense of clarity within the context of outbreak conditions.



Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials

It is shown that the semiparametric methods estimate both efficacy parameters without bias when the good exposure information is either missing completely at random or missing at random.

Study designs for evaluating different efficacy and effectiveness aspects of vaccines.

A framework of study designs is presented that relates the scientific question of interest to the choice of comparison groups, the unit of observation, the level of information available for analysis, and the parameter of effect.

Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand.

Using plausible epidemiologic assumptions and controlling for behavioral risks, the authors found that a significantly higher transmission probability was associated with sub type E compared with subtype B in this population of injecting drug users in Bangkok.

Mixture models in measurement error problems, with reference to epidemiological studies

Summary. The paper focuses on a Bayesian treatment of measurement error problems and on the question of the specification of the prior distribution of the unknown covariates. It presents a flexible

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

The vaccine did not prevent HIV-1 acquisition and there was no overall protective effect, but the efficacy trends in subgroups may provide clues for the development of effective immunization approaches.

Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand.

  • D. KitayapornS. Vanichseni J. Esparza
  • Medicine
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
  • 1998
Although HIV-1 subtype B' accounts for most prevalent infections, subtype E seems to be more prevalent among younger IDUs, and most infections seem likely to result from parenteral transmission.

A Bayesian approach to measurement error problems in epidemiology using conditional independence models.

A Bayesian perspective on measurement error problems in epidemiology is taken and it is shown how the information available in this setting can be structured in terms of conditional independence models.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Despite the successful completion of this efficacy trial of AIDSVAX B/E (VaxGen), the vaccine did not prevent HIV-1 infection or delay HIV- 1 disease progression.

Bayes inference in regression models with ARMA (p, q) errors

Inference from Iterative Simulation Using Multiple Sequences

The focus is on applied inference for Bayesian posterior distributions in real problems, which often tend toward normal- ity after transformations and marginalization, and the results are derived as normal-theory approximations to exact Bayesian inference, conditional on the observed simulations.